Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 70.44% higher on its value in year-to-date trading and has touched a low of $7.86 and a high of $17.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $14.33 in the last trading session, with the day’s loss setting it -12.14%.
Currently trading at $2.19M, the stock is 5.50% and 3.90% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.16 million and changing 2156808% at the moment leaves the stock 13.73% off its SMA200. ARQT registered 3.88% gain for a year compared to 6-month loss of 2.55%. The firm has a 50-day simple moving average (SMA 50) of $13.9267 and a 200-day simple moving average (SMA200) of $12.723125.
The stock witnessed a 3.51% gain in the last 1 month and extending the period to 3 months gives it a -15.43%, and is 9.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.93% over the week and 2.66% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 342 employees, a market worth around $1.72B and $212.82M in sales. Fwd P/E is 73.72. Profit margin for the company is -60.95%. Distance from 52-week low is 84.10% and -18.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.35%).
The EPS is expected to grow by 52.31% this year
325.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 111.09% of the company’s shares. The shares outstanding are 119.14M, and float is at 104.80M with Short Float at 16.01%. Institutions hold 108.90% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712 of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95 and valued at over $91.3 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.1147 of the shares totaling 8.79 million with a market value of $81.7 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Welgus Howard G., the company’s Director. SEC filings show that Welgus Howard G. sold 10,139 shares of the company’s common stock on Jun 18 ’25 at a price of $13.37 per share for a total of $0.14 million. Following the sale, the insider now owns 0.11 million shares.
Still, SEC filings show that on Jun 13 ’25, Heron Patrick J (Director) acquired 2,646 shares at an average price of $13.08 for $34610.0. The insider now directly holds 27,448 shares of Arcutis Biotherapeutics Inc (ARQT).
